Spectrum Pharmaceuticals, Inc. Class Action Lawsuit - SPPI

(i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the SPPI class action lawsuit, you must have incurred a loss on shares of Spectrum purchased during the class period listed above.

If you suffered a loss in Spectrum during the relevant time frame or pursuant to the relevant offering(s), you have until November 1, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.